Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 7/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FOS | P01100 | 2/20 | 0.35 |
| ▸ | JUN | P05412 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | F13A1 | P00488 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206406 | 0.92 | FOS (0.35) | LTB4RLTB4R2FOSJUNFFAR1 | |
| SCHEMBL26206155 | 0.90 | PPARG (0.34) | IDO1MAPTMPO | |
| SCHEMBL26206467 | 0.85 | LTB4R (0.46) | LTB4RLTB4R2FOSJUN | |
| SCHEMBL26206421 | 0.84 | LTB4R (0.44) | LTB4RLTB4R2FOSJUNMPO | |
| SCHEMBL26206433 | 0.83 | F13A1 (0.37) | LTB4RLTB4R2TSHRFOSJUN | |
| SCHEMBL26206478 | 0.82 | FOS (0.38) | LTB4RLTB4R2TSHRFOSJUN | |
| SCHEMBL26206481 | 0.82 | TSHR (0.44) | TSHRFFAR1FFAR4MAPTRXFP1 | |
| SCHEMBL26206385 | 0.82 | FOS (0.36) | LTB4RLTB4R2TSHRFOSJUN | |
| SCHEMBL26206158 | 0.81 | MAPT (0.34) | MAPTTMPRSS15 | |
| SCHEMBL26206437 | 0.81 | F13A1 (0.37) | LTB4RLTB4R2FOSJUNFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | LTB4R 2439/4885LTB4R2 2981/4885TSHR 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.